NSE - Delayed Quote INR

Ambuja Cements Limited (AMBUJACEM.NS)

638.35 -6.10 (-0.95%)
At close: 3:29 PM GMT+5:30
Loading Chart for AMBUJACEM.NS
DELL
  • Previous Close 644.45
  • Open 644.00
  • Bid --
  • Ask --
  • Day's Range 629.20 - 649.00
  • 52 Week Range 375.75 - 649.00
  • Volume 3,366,352
  • Avg. Volume 3,627,659
  • Market Cap (intraday) 1.572T
  • Beta (5Y Monthly) 0.12
  • PE Ratio (TTM) 70.77
  • EPS (TTM) 9.02
  • Earnings Date Jun 25, 2024 - Jun 29, 2024
  • Forward Dividend & Yield 2.50 (0.39%)
  • Ex-Dividend Date Jul 7, 2023
  • 1y Target Est --

Ambuja Cements Limited, together with its subsidiaries, manufactures and markets cement and cement related products to individual homebuilders, masons and contractors, and architects and engineers in India. The company offers Portland pozzolana cement and ordinary Portland cement, as well as temperature resistant concrete blocks, Blaine Portland cement, and micro materials. It sells its products through dealers, authorized retail stockiest, retailers, and authorized sales representatives. The company was formerly known as Gujarat Ambuja Cements Limited and changed its name to Ambuja Cements Limited in April 2007. The company was incorporated in 1981 and is based in Mumbai, India. Ambuja Cements Limited operates as a subsidiary of Holderind Investments Ltd.

www.ambujacement.com

4,361

Full Time Employees

March 31

Fiscal Year Ends

Recent News: AMBUJACEM.NS

Performance Overview: AMBUJACEM.NS

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AMBUJACEM.NS
22.55%
S&P BSE SENSEX
2.91%

1-Year Return

AMBUJACEM.NS
68.83%
S&P BSE SENSEX
23.78%

3-Year Return

AMBUJACEM.NS
122.13%
S&P BSE SENSEX
55.27%

5-Year Return

AMBUJACEM.NS
216.59%
S&P BSE SENSEX
90.35%

Compare To: AMBUJACEM.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AMBUJACEM.NS

Valuation Measures

Annual
As of 4/24/2024
  • Market Cap

    1.59T

  • Enterprise Value

    1.46T

  • Trailing P/E

    71.37

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.23

  • Price/Book (mrq)

    4.82

  • Enterprise Value/Revenue

    4.84

  • Enterprise Value/EBITDA

    34.26

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.82%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    322.32B

  • Net Income Avi to Common (ttm)

    31.67B

  • Diluted EPS (ttm)

    9.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    129.72B

  • Total Debt/Equity (mrq)

    1.85%

  • Levered Free Cash Flow (ttm)

    --

Company Insights: AMBUJACEM.NS

People Also Watch